Fineline Cube

Follow:
14398 Articles
CompanyDrug

J&J’s TECVAYLI Shows 71% PFS Reduction in Phase 3 MajesTEC‑9 for Multiple Myeloma

Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011
CompanyDeals

Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011

Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline
CompanyDeals

Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline

Sunshine Lake Pharma Launches AI-Powered PROTAC Platform to Target Undruggable Proteins
CompanyDigital

Sunshine Lake Pharma Launches AI-Powered PROTAC Platform to Target Undruggable Proteins

QYuns' QX030N Partner Caldera Raises $112.5 Million for IBD Bispecific
CompanyDeals

QYuns’ QX030N Partner Caldera Raises $112.5 Million for IBD Bispecific

Leads Biolabs' Opamtistomig Secures FDA Fast Track for EP-NEC as First 4-1BB Bispecific
CompanyDrug

Leads Biolabs’ Opamtistomig Secures FDA Fast Track for EP-NEC as First 4-1BB Bispecific

Company

WuXi Biologics Secures MHRA GMP Certification for Ophthalmic Biologic Manufacturing Facilities

CompanyDeals

NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development

CompanyDeals

AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D

Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund
CompanyDeals

Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund

Company

WuXi AppTec Projects 2025 Revenue of $6.51 Billion, Net Profit Surges 103% on Divestments

Fosun Kairos Inks Vitalgen Tech Deal to Develop In‑Vivo CAR‑T for Autoimmune Diseases
CompanyDeals

Fosun Kairos Inks Vitalgen Tech Deal to Develop In‑Vivo CAR‑T for Autoimmune Diseases